Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1

PLoS One. 2014 Feb 28;9(2):e90298. doi: 10.1371/journal.pone.0090298. eCollection 2014.

Abstract

Eosinophils play a central role in asthma. The present study was performed to investigate the effect of tumour necrosis factor-α (TNF-α) on longevity of isolated human eosinophils. In contrast to Fas, TNF-α inhibited eosinophil apoptosis as evidenced by a combination of flow cytometry, DNA fragmentation assay and morphological analyses. The effect of TNF-α on eosinophil apoptosis was reversed by a TNF-α neutralising antibody. The anti-apoptotic effect of TNF-α was not due to autocrine release of known survival-prolonging cytokines interleukins 3 and 5 or granulocyte-macrophage-colony-stimulating factor as their neutralisation did not affect the effect of TNF-α. The anti-apoptotic signal was mediated mainly by the TNF-receptor 1. TNF-α induced phosphorylation and degradation of IκB and an increase in NF-κB DNA-binding activity. The survival-prolonging effect of TNF-α was reversed by inhibitors of NF-κB pyrrolidinedithiocarbamate and gliotoxin and by an inhibitor of IκB kinase, BMS-345541. TNF-α induced also an increase in AP-1 DNA-binding activity and the antiapoptotic effect of TNF-α was potentiated by inhibitors of AP-1, SR 11302 and tanshinone IIA and by an inhibitor of c-jun-N-terminal kinase, SP600125, which is an upstream kinase activating AP-1. Our results thus suggest that TNF-α delays human eosinophil apoptosis via TNF-receptor 1 and the resulting changes in longevity depend on yin-yang balance between activation of NF-κB and AP-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / pharmacology
  • Apoptosis / drug effects
  • Asthma / genetics*
  • Asthma / metabolism
  • Asthma / pathology
  • Cell Survival / drug effects
  • Eosinophils / drug effects
  • Eosinophils / metabolism*
  • Eosinophils / pathology
  • Gene Expression Regulation
  • Gliotoxin / pharmacology
  • Humans
  • I-kappa B Kinase / antagonists & inhibitors
  • I-kappa B Kinase / genetics
  • I-kappa B Kinase / metabolism
  • Imidazoles / pharmacology
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics*
  • NF-kappa B / metabolism
  • Phosphorylation
  • Primary Cell Culture
  • Protein Binding
  • Pyrrolidines / pharmacology
  • Quinoxalines / pharmacology
  • Receptors, Tumor Necrosis Factor, Type I / genetics
  • Receptors, Tumor Necrosis Factor, Type I / metabolism*
  • Retinoids / pharmacology
  • Signal Transduction
  • Thiocarbamates / pharmacology
  • Transcription Factor AP-1 / antagonists & inhibitors
  • Transcription Factor AP-1 / genetics*
  • Transcription Factor AP-1 / metabolism
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / pharmacology*
  • fas Receptor / pharmacology

Substances

  • 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline
  • Antibodies
  • FAS protein, human
  • Imidazoles
  • NF-kappa B
  • Pyrrolidines
  • Quinoxalines
  • Receptors, Tumor Necrosis Factor, Type I
  • Retinoids
  • SR 11302
  • Thiocarbamates
  • Transcription Factor AP-1
  • Tumor Necrosis Factor-alpha
  • fas Receptor
  • pyrrolidine dithiocarbamic acid
  • Gliotoxin
  • I-kappa B Kinase